Lung Cancer Highlights from ASCO 2026

Prof. Mark Socinski joined us at ASCO 2026 to share his views on the latest breaking lung cancer data coming from the congress. How could data from key lung cancer trials impact clinical practice? Watch to find out. Prof. Socinski reviews data from the following: 𝗟𝗜𝗕𝗥𝗘𝗧𝗧𝗢-𝟰𝟯𝟮: Event-free survival with adjacent selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial. Goldman J, et al. Abstract LBA3, ASCO 2026 𝗪𝗨-𝗞𝗢𝗡𝗚𝟮𝟴: Sunvozertinib monotherapy versus platinum-based chemotherapy as 1st line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomised study (WU-KONG28). Heymach J.V, et al. Abstract LBA8500, ASCO 2026 𝗛𝗔𝗥𝗠𝗢𝗡𝗶-𝟲: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC: Overall survival results of the phase 3 HARMONi-6 trial. Zhiwei C, et al. Abstract LBA4, ASCO 2026 (Presenter Lu S) Get more updates from ASCO 2026 in HER2-mutant NSCLC, prostate cancer, GI and hepatobiliary cancers, and breast cancer: https://cor2ed.com/n-connect/programm... Follow us on social media: LinkedIn LUNG CONNECT:   / lungconnect   PRECISION ONCOLOGY CONNECT:   / ntrk-connect   X LUNG CONNECT: https://x.com/lung_connect PRECISION ONCOLOGY CONNECT: https://x.com/PresOnc_Connect Instagram:   / cor2edmeded     This content is intended for healthcare professionals only. Video developed by cor2ed.com Published June 2026. Subscribe to this channel to stay up to date with new Independent Education programmes as they're released. #LungCancer #MedicalEducation #ASCO2026 #PrecisionMedicine